Search research articles
Contact Us
Filters
Showing results (81-90 of 98) with videos related to
Page
of 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2020
Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)
Mario Mandalà, Francesca Galli, Roberto Patuzzo, et al.
The Oncologist
|
January 17, 2020
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis
Gerardo Rosati, Fabio Galli, Maurizio Cantore, et al.
Clinical Colorectal Cancer
|
March 19, 2023
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial
Debora Basile, Gerardo Rosati, Francesca Bergamo, et al.
Journal of Cardiac Failure
|
March 21, 2025
Medical Treatments in Patients With Ambulatory Heart Failure: First Data From the BRING-UP-3 Heart Failure Study
Fabrizio Oliva, Francesco Orso, Furio Colivicchi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
Gerardo Rosati, Sara Lonardi, Fabio Galli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)
Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
Scientific Reports
|
August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports
|
February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
British Journal of Cancer
|
October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
A Ruzzo, F Graziano, Fabio Galli, et al.
Frontiers in Oncology
|
April 24, 2025
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice
Stefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 98) with videos related to
Sort By:
Page
of 10
European Journal of Cancer (Oxford, England : 1990)
|
August 3, 2020
Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)
Mario Mandalà, Francesca Galli, Roberto Patuzzo, et al.
The Oncologist
|
January 17, 2020
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis
Gerardo Rosati, Fabio Galli, Maurizio Cantore, et al.
Clinical Colorectal Cancer
|
March 19, 2023
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial
Debora Basile, Gerardo Rosati, Francesca Bergamo, et al.
Journal of Cardiac Failure
|
March 21, 2025
Medical Treatments in Patients With Ambulatory Heart Failure: First Data From the BRING-UP-3 Heart Failure Study
Fabrizio Oliva, Francesco Orso, Furio Colivicchi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
Gerardo Rosati, Sara Lonardi, Fabio Galli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 8, 2026
Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49)
Nicoletta Colombo, Gabriella Parma, Giulia Tasca, et al.
Scientific Reports
|
August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports
|
February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
British Journal of Cancer
|
October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
A Ruzzo, F Graziano, Fabio Galli, et al.
Frontiers in Oncology
|
April 24, 2025
Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice
Stefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Page
of 10